Genmab A/S (OTCMKTS:GNMSF) Hits New 1-Year High - What's Next?

Key Points

• Genmab A/S shares reached a new 52-week high at $280.00, a significant increase from the previous close of $277.60.
• The company reported a robust quarterly earnings result with $5.42 earnings per share (EPS), exceeding the consensus estimate by $1.43.
• Genmab has a market capitalization of $18.78 billion and a return on equity of 21.03%, reflecting its strong financial performance in the biotechnology sector.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $280.00 and last traded at $280.00, with a volume of 415 shares traded. The stock had previously closed at $277.60.

Genmab A/S Stock Up 0.3%

The stock has a market cap of $18.83 billion, a P/E ratio of 14.31 and a beta of 0.90. The stock has a fifty day simple moving average of $234.55 and a 200-day simple moving average of $214.62.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.99 by $1.43. The firm had revenue of $925.00 million for the quarter, compared to analysts' expectations of $949.06 million. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.